Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychother ...

Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no ...

Mental health is not just depression, schizophrenia, a mood disorder, anxiety; it has all of the things. We are trying to ...

Supporters believe that FDA approval will make the drug more accessible. Right now, traditional psilocybin therapy offered at healing centers in the state is not covered by insurance.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Mental health care continues to grow in Central Virginia and now, one Lynchburg clinic is celebrating two years of providing unique, science-backed treatment options.

Esketamine monotherapy demonstrated beneficial antidepressant effects at multiple doses for patients with treatment-resistant depression, according to results of a phase 4 randomized trial published ...

On Friday, July 18, the Lynchburg Regional Business Alliance and Credence Behavioral Health officially cut the ribbon to ...

Once used only as an anesthetic, ketamine is now among the fastest-acting tools in mental healthcare — a proven treatment for PTSD and more.

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage ...

Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to ...